Bieche I, Parfait B, Tozlu S, Lidereau R, Vidaud Yards: Quantitation out of androgen receptor gene term in the sporadic nipple tumors of the real-time RT-PCR: evidence you to definitely MYC are an enthusiastic AR-managed gene. Carcinogenesis. 2001, twenty-two (9): 1521-1526. /carcin/twenty-two.nine.1521.
Bratthauer GL, Lininger RA, Child YG, Tavassoli FA: Androgen and the hormone estrogen receptor mRNA standing for the apocrine carcinomas. Diagn Mol Pathol. 2002, eleven (2): 113-118. 9606-200206000-00008.
Gatalica Z: Immunohistochemical investigation of apocrine breast lesions. Consistent more-term off androgen receptor followed closely by the increasing loss of the hormone estrogen and you can progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol Res Pract. 1997, 193 (11-12): 753-758.
Are J Clin Pathol
Soreide JA, Lea OA, Varhaug JE, Skarstein An excellent, Kvinnsland S: Androgen receptors inside the operable cancer of the breast: reference to most other steroid hormones receptors, correlations so you’re able to prognostic things and predictive really worth to own aftereffect of adjuvant tamoxifen procedures. Eur J Surg Oncol. 1992, 18 (2): 112-118.
Bayer-Garner IB, Smoller B: Androgen receptors: good marker to improve awareness having identifying breast cancer from inside the body metastasis out of not familiar pri, 13 (2): 119-122. /modpathol.3880021.
Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and systematic ramifications. J Clin Oncol. 2000, 18 (5): 1135-1149.
Pang ST, Flores-Morales An effective, Skoog L, Chuan YC, Nordstedt G, Pousette A good: Regulation of matrix metalloproteinase thirteen phrase because of the androgen within the prostate cancers. Oncol Associate. 2004, 11 (6): 1187-1192.
Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ: Androgen receptors in breast cancer. Cancer. 1984, 54 (11): 2436-2440. -0142(19841201)3.0.
Schippinger W, Regitnig P, Dandachi Letter, Wernecke KD, Bauernhofer T, Samonigg H, Moinfar F: Evaluation of your prognostic requirement for androgen receptor expression within the metastatic cancer of the breast. Virchows Arch. 2006, 449 (1): 24-31. /s00428-00six-0213-6.
Parker RL, Huntsman DG, Lesack DW, Cupples JB, Grant DR, Akbari M, Gilks CB: Investigations of interlaboratory adaptation on immunohistochemical devotion out-of estrogen receptor position using a breast cancer cells microarray. 2002, 117 (5): 723-728. /PEF8-GL6F-YWMC-AG56.
Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, , Garcia-Muniz JL: Examination of matrix metalloproteinases and their inhibitors in cancer of the breast. Br J Cancers. 2007, 96 (6): 903-911. /sj.bjc.6603666.
Narita D, Raica M, Suciu C, Cimpean A, Anghel An excellent: Immunohistochemical phrase from androgen receptor and you can prostate-certain antigen for the cancer of the breast. Folia Histochem Cytobiol. 2006, 49 (3): 165-172.
Egeblad Meters, Werb Z: The fresh new properties toward matrix metalloproteinases inside malignant tumors development. Nat Rev Cancer tumors. 2002, 2 (3): 161-174. /nrc745.
Turk V, Kos J, Turk B: Cysteine cathepsins (proteases)–into head stage regarding disease?. Malignant tumors Cellphone. 2004, 5 (5): 409-410. /S1535-6108(04)00117-5.
Manes S, Llorente M, Lacalle RA, Gomez-Mouton C, Kremer L, Mira E, Martinez Air-conditioning: The new matrix metalloproteinase-nine manages this new insulin-particularly progress grounds-caused autocrine reaction inside the DU-145 carcinoma muscle. J Biol Chem. 1999, 274 (11): 6935-6945. /jbc..
Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel Elizabeth, Matrisian LM, Mareel Yards: Launch of an invasion promoter E-cadherin fragment because of the matrilysin and stromelysin-1. J Cell Sci. 2001, 114 (Pt step 1): 111-118.
Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM: Matrilysin [MMP-7] phrase chooses getting muscle with reduced awareness in order to apoptosis. Neoplasia. 2001, 3 muslima eÅŸleÅŸme sorunu (6): 459-468. /sj.neo.7900190.
CO;2-H
Stetler-Stevenson WG: Matrix metalloproteinases into the angiogenesis: a moving target to own therapeutic intervention. J Clin Dedicate. 1999, 103 (9): 1237-1241. /JCI6870.
Cornelius Los angeles, Nehring LC, Harding Elizabeth, Bolanowski Meters, Welgus HG, Kobayashi DK, Pierce RA, Shapiro SD: Matrix metalloproteinases make angiostatin: consequences into neovascularization. J Immunol. 1998, 161 (12): 6845-6852.
Jiang Y, Goldberg ID, Shi YE: State-of-the-art positions regarding tissues inhibitors off metalloproteinases in the malignant tumors. Oncogene. 2002, 21 (14): 2245-2252. /sj.onc.1205291.
